Intermediate term outcomes with bifurcation coronary stenting using the paclitaxel drug-eluting stent: a single centre experience.

Background: Percutaneous treatment of bifurcation coronary artery disease (BCD) is complex and, in the era of bare metal stents (BMS), was reported to have a high rate of repeat target lesion revascularization (TLR). Paclitaxel drug-eluting stents (PES) have been used in the treatment of BCD, with better overall outcomes than BMS. Also, acute stent thrombosis (AST), with an incidence ranging from 2.

Long-term outcomes in treating left main trifurcation coronary artery disease with the Paclitaxel-eluting stent.

Background: Left main trifurcation coronary artery disease stenting is a challenging and complex percutaneous procedure that has been infrequently reported. We present our own experience with left main trifurcation stenting using the Taxus paclitaxel-eluting stent (Boston Scientific).

Methods: Twenty consecutive left main trifurcation stenting procedures were performed in 2005 at our institution.